354 Recruiting Trials

Clinical Trials
in Idaho

Browse 354 recruiting clinical trials currently enrolling participants in Idaho. Search by condition to find trials you may qualify for, at no cost.

Showing 15 of 354 recruiting trials in Idaho

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
PHASE2 Anchorage, Alaska +4 sites · Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma
Recruiting
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
PHASE2 Birmingham, Alabama +4 sites · Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
PHASE3 Anchorage, Alaska +4 sites · Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Recruiting
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
PHASE3 Anchorage, Alaska +4 sites · Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Recruiting
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
PHASE3 Birmingham, Alabama +4 sites · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
PHASE2 Anchorage, Alaska +4 sites · Resectable Pancreatic Adenocarcinoma, Pancreatic Acinar Cell Carcinoma
Recruiting
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
PHASE2 Anchorage, Alaska +4 sites · Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
PHASE3 Birmingham, Alabama +4 sites · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
PHASE2 Phoenix, Arizona +4 sites · Muscle Invasive Bladder Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
PHASE3 Birmingham, Alabama +4 sites · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Recruiting
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
PHASE3 Fayetteville, Arkansas +4 sites · Stage IV Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Recruiting
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
PHASE3 Phoenix, Arizona +4 sites · Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8
Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
PHASE2 Berkeley, California +4 sites · Myelodysplastic Syndrome
Recruiting
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
PHASE3 Birmingham, Alabama +4 sites · Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
PHASE3 Birmingham, Alabama +4 sites · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Recruiting
See all 354 results in Idaho

Check Your Eligibility

Create a free profile and our AI will match you to trials in Idaho you may qualify for.

Get Matched — Free
No insurance required
Search by Condition in Idaho
Diabetes Cancer Breast Cancer Depression Anxiety Alzheimer's Heart Disease Asthma Multiple Sclerosis Obesity Parkinson's Lupus Hypertension COPD Stroke Arthritis Kidney Disease COVID-19
Browse Other States
California Texas New York Florida Illinois Pennsylvania Ohio Georgia North Carolina Michigan New Jersey Washington Arizona Massachusetts Tennessee Colorado Minnesota Maryland Wisconsin Oregon